Shield Therapeutics shares jump after potential landmark regulatory filing
Commercial-stage pharmaceutical company focused on treating iron deficiency Shield Therapeutics (STX:AIM) said its lead product Accrufer had been submitted for regulatory review in Canada.If approved the drug would become the first...
21 March 2022